Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.

MLA

Huang, Yiqing, et al. “Real-World Experience of Consolidation Durvalumab after Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer.” Thoracic Cancer, vol. 13, no. 22, Nov. 2022, pp. 3152–61. EBSCOhost, https://doi.org/10.1111/1759-7714.14667.

APA

Huang, Y., Zhao, J. J., Soon, Y. Y., Wong, A., Aminkeng, F., Ang, Y., Asokumaran, Y., Low, J. L., Lee, M., Choo, J. R. E., Chan, G., Kee, A., Tay, S. H., Goh, B. C., & Soo, R. A. (2022). Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Thoracic Cancer, 13(22), 3152–3161. https://doi.org/10.1111/1759-7714.14667

Chicago

Huang, Yiqing, Joseph J Zhao, Yu Yang Soon, Alvin Wong, Folefac Aminkeng, Yvonne Ang, Yugarajah Asokumaran, et al. 2022. “Real-World Experience of Consolidation Durvalumab after Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer.” Thoracic Cancer 13 (22): 3152–61. doi:10.1111/1759-7714.14667.